Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$3.15 - $808.8 $3.92 Million - $1.01 Billion
-1,243,976 Closed
0 $0
Q2 2022

Aug 12, 2022

SELL
$3.0 - $10.45 $7.57 Million - $26.4 Million
-2,521,922 Reduced 66.97%
1,243,976 $622,000
Q1 2022

May 12, 2022

SELL
$7.57 - $21.72 $273,367 - $784,352
-36,112 Reduced 0.95%
3,765,898 $2.73 Million
Q4 2021

Feb 10, 2022

BUY
$19.68 - $28.68 $1.67 Million - $2.44 Million
85,067 Added 2.29%
3,802,010 $6.46 Million
Q3 2021

Nov 09, 2021

BUY
$26.16 - $40.68 $97.2 Million - $151 Million
3,716,943 New
3,716,943 $8.1 Million

Others Institutions Holding AVTX

# of Institutions
1
Shares Held
34.6K
Call Options Held
0
Put Options Held
0

About Avalo Therapeutics, Inc.


  • Ticker AVTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 9,414,100
  • Market Cap $84.9M
  • Description
  • Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the tr...
More about AVTX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.